The pathogenesis of familial hyperuricemia has been investigated in two kindreds in whom hyperuricemia was present in members of successive generations. Enzymatic and metabolic studies, including the incorporation of isotopically labeled glycine into urinary uric acid and assessment of the total excretion of oxypurines in one family, excluded a metabolic etiology. No secondary cause of hyperuricemia was identified in either family. Fractional excretion of uric acid was less than 6.2% in all hyperuricemic individuals studied, while creatinine clearances were normal. Tubular secretion of uric acid and tubular reabsorption of uric acid were studied in an affected teenager from each family while receiving a purine-free diet. Inhibition of secretion of uric acid with pyrazinamide decreased fractional excretion of uric acid to 0.6% in patient S and to 0.7% in patient B. Tubular secretion of uric acid at maximal response to pyrazinamide in these patients was 0.393 and 0.410 mg/dl glomerular filtration rate (nl response 0.300 to 1.30 mg/min/100 ml inulin clearance). Probenecid, an inhibitor of uric acid reabsorption, increased uric acid excretion by 3.9 mumin and by 3.2 mg/min (nl response 1.7 + 0.3 mumin) in ~atients S and B. Tubular reabsor~tion of uric acid distal to secretory sites was determined by assessing the uricosuric response to probenecid plus pyrazinamide. Uric acid excretion increased by only 0.08 mg/min in patient A and by 0.17 mg/min in patient B (nl response 0.9 mumin). Ascorbic acid increased fractional excretion of uric acid by 7.2% in patient S but was not uricosuric in patient B or any hyperuricemic member of his family. These data suggest that hyperuricemia in these families is due to diminished renal clearance of uric acid and that the reduced clearance is,due to increased tubular reabsorption of uric acid distal to secretory sites.
Summary
The pathogenesis of familial hyperuricemia has been investigated in two kindreds in whom hyperuricemia was present in members of successive generations. Enzymatic and metabolic studies, including the incorporation of isotopically labeled glycine into urinary uric acid and assessment of the total excretion of oxypurines in one family, excluded a metabolic etiology. No secondary cause of hyperuricemia was identified in either family. Fractional excretion of uric acid was less than 6.2% in all hyperuricemic individuals studied, while creatinine clearances were normal. Tubular secretion of uric acid and tubular reabsorption of uric acid were studied in an affected teenager from each family while receiving a purine-free diet. Inhibition of secretion of uric acid with pyrazinamide decreased fractional excretion of uric acid to 0.6% in patient S and to 0.7% in patient B. Tubular secretion of uric acid at maximal response to pyrazinamide in these patients was 0.393 and 0.410 mg/dl glomerular filtration rate (nl response 0.300 to 1.30 mg/min/100 ml inulin clearance). Probenecid, an inhibitor of uric acid reabsorption, increased uric acid excretion by 3.9 mumin and by 3.2 mg/min (nl response 1.7 + 0.3 mumin) in ~atients S and B. Tubular reabsor~tion of uric acid distal to secretory sites was determined by assessing the uricosuric response to probenecid plus pyrazinamide. Uric acid excretion increased by only 0.08 mg/min in patient A and by 0.17 mg/min in patient B (nl response 0.9 mumin). Ascorbic acid increased fractional excretion of uric acid by 7.2% in patient S but was not uricosuric in patient B or any hyperuricemic member of his family. These data suggest that hyperuricemia in these families is due to diminished renal clearance of uric acid and that the reduced clearance is,due to increased tubular reabsorption of uric acid distal to secretory sites.
Speculation
The pathogenetic mechanism in individuals with familial hyperuricemia may differ from patients with sporadic gout. In some families, hyperuricemia may be due to increased tubular reabsorp tion of uric acid distal to secretory sites in the nephron. Such patients might benefit from judicious therapy with agents which inhibit tubular urate reabsorption.
Gout has been recognized since antiquity to be familial. In the United States, nearly 40% of patients with symptomatic hyperuricemia have a relative with gout (40) , and asymptomatic hyperuricemia has been identified in as many as 27% of relatives of patients with gout (39) . However, large kindreds in which simple Mendelian patterns of inheritance are demonstrable are not frequently encountered. Families in which there is severe, symptomatic hyperuricemia resulting in early death are even more uncommon. It is customary to consider that the pathogenesis of hyperuricemia in kindreds demonstrating these characteristics is a result of overproduction of purine de novo as a consequence of an enzymatic abnormality, such as those of hypoxanthine guanine phosphoribosyl transferase (16) or phosphoribosyl pyrophosphate synthetase (4). However, families are sometimes encountered in which there is no evidence of overproduction, and hyperuricemia appears to be renal in nature. The elucidation of the pathogenesis of the elevated concentrations of uric acid in large kindreds with distinct patterns of inheritance should lead to insights on the control of genetic determinants of hyperuricemia and on genetic mechanisms in renal physiology. Their elucidation may have broader implications for the pathogenesis of hyperuricemia in other patients with familial or sporadic hyperuricemia.
It is the purpose of this report to describe studies on the pathogenesis of hyperuricemia in two kindreds in whom hyperuricemia was present in family members of successive generations. In both families the renal excretion of uric acid was diminished with evidence supporting increased renal tubular reabsorption of uric acid.
PATIENTS FAMILY S.
SIV2 was a 17-year-old white male in whom an elevated serum concentration of uric acid of 11.9 mg/dl had originally been discovered through routine testing initiated because of the occurrence of hyperuricemia and clinical gout in a number of members of his family (Table 1, Fig. 1 ). Each of his siblings had hyperuricemia (serum uric acid >7.0 mg/dl), and males and females were affected in at least three generations. An uncle and a grand uncle had had severe tophaceous gout and had died at the ages of 36 and 23 years, respectively. The tophi in the uncle became necrotic and exposed bone over the ribs and vertebrae. In each, the onset of attacks of gouty arthritis was in the middle teen years. In contrast, the 67-year-old maternal grand aunt had no manifestations other than hyperuricemia. The father was 42 years old and had a serum concentration of uric acid of 10 mg/dl which decreased to normal levels with dietary therapy and allopurinol. There were no other known instances of hyperuricemia or clinical gout in the father's family.
The patient developed aching of the fingers and toes at the age of 16 years. These pains disappeared when treatment was started with allopurinol (500 mg daily). He had a fractured clavicle at birth and fractures of the thumb and a finger during athletic competition. Osgood-Schlatter disease developed at age 13 years but resolved without change in his vigorous athletic activity. He was at the appropriate grade level andan average student.
Physical examination revealed a muscular, healthy appearing adolescent. The blood pressure was 112/68 mm Hg, height was 185 cm, weight 64 kg, and the body surface area 1.82 m2. There were no tophi. The physical examination, including the musculo-skeletal was normal without limitation of mobility or tenderness in either the large or small joints.
Laboratory evaluation indicated serum concentrations of uric Clinical data for hyperuricemic family members, SI14, SI15, SIV1-+ who were evaluated in the Clinical Research Center, and SI19 are summarized in Table 1 .
FAMILY B
BIIs was a 17-year-old white male in whom an elevated serum concentration of uric acid of 11.5 mg/dl was discovered at a routine preschool physical examination. He was entirely asymptomatic and was taking no medications. He was an above-average student and grade-appropriate. There was no family history of gout or renal disease. He had been noted to have asymptomatic proteinuria during a routine physical examination at the age of 14 years. Evaluation at that time demonstrated a normal creatinine clearance, normal excretory urogram, and orthostatic proteinuria. He had subsequently been examined at yearly intervals; his creatinine clearance, urinalyses and 24-hr protein excretion have been normal since 15 years of age.
Physical examination revealed a healthy adolescent whose height was 182 cm, weight was 83.2 kg, and blood pressure was 124/82 mmHg. There were no tophi and examination of the musculoskeletal and neurologic systems were normal.
Laboratory data included; hemoglobin 14.8 g/dl, white blood cell count 8,600 mm3, platelet count 300,000/mm3, reticulocyte count 1.0%, sodium 143, potassium 4.5, chloride 105, and bicarbonate 26 mEq/liter, urea nitrogen 16, and creatinine 1.1 mg/dl.
During the evaluation of this patient, hyperuricemia was discovered in the father and four brothers (Fig. 1) . All of the members of the family who had hyperuricemia were asymptomatic. A complete blood count, and the serum concentrations of electrolytes and urea nitrogen and the creatinine clearance were normal in all members of the family.
MATERIALS AND METHODS
Uric acid was determined using the enzymatic spectrophotometric method (18) . Hypoxanthine guanine phosphoribosyltransferase (HGPRT) and adenine phosphoribosyltransferase (APRT) were assayed in erythrocyte lysates using the method of Bakay et al. (3) . These enzymes were also examined electrophoretically (1, 3) . Urinary oxypurines were quantitated after separation on cation exchange columns (38). Urinary organic acids were studied according to the method of Sweetman (35) . The rate of synthesis of purines was studied by the intravenous administration of glycine uniformally labeled with 14C in a dose of 2 pCi/kg along with 50 mg/kg of glycine-I, 2-13C which was 9.5% enriched with 13C (17, 36) , collection of the urine for 7 days in 24-hr aliquots, isolation and purification of the uric acid excreted, and determination of its isotope content. Creatinine and phosphorus values were determined utilizing the Autoanalyzer technique (Technicon Corp., Tarrytown, NY). Sodium was measured by flame photometry.
Protein-binding of uric acid was determined by equilibration dialysis using cellophane dialysis tubing of %-inch diameter. The dialysis tubing was initially heated to boiling in distilled water and then washed repeatedly in distilled water. One-milliliter serum samples were tied in the dialysis tubing and then dialyzed at 37OC against a solution of 0.05 M sodium phosphate buffer, pH 7.4, containing 5 mg/dl uric acid, 5 mg/dl sodium azide, and trace amounts of 2-14C uric acid. After 30 hr, 1.0-ml aliquots of both serum and bath were counted in duplicate. The degree of binding is expressed as the ratio of uric acid in the serum divided by the uric acid in the bath. No correction was made for the GibbsDonnan effect.
An adolescent with hyperuricemia from each family (indicated by the arrows in Fig. 1 ) was admitted to the Clinical Research Center in order to evaluate the renal handling of uric acid. Each was given an isocaloric, purine-free, 3-g sodium diet for 3 days before and throughout the period of study. No medications were taken for at least 1 week before the study.
On the fifth hospital day, a pyrazinarnide suppression test (22) was performed. After an overnight fast, 20 ml/kg of tap water was taken orally. Hydration thereafter during the study consisted of oral tap water equal to urine volume. Two or three 30-min control collections of urine were obtained and venous blood specimens collected midway in the first period and at the end of the third period. Immediately after the control periods, 3.0 g pyrazinamide was given orally. Five or six 30-min collections of urine were then obtained with midpoint venous blood samples drawn during the fourth and final collection period. Samples of urine and blood were analyzed for creatinine, phosphorus, sodium, and uric acid. Clearances were calculated using the standard formula; serum values were determined by constructing a midpoints curve. Pyrazinamide-suppressible uric acid excretion was calculated at the maximal decrement in excretion of uric acid from the mean of the control periods. The influence of probenecid 2.0 g, probenecid 2.0 g plus pyrazinamide 3.0 g, and ascorbic acid 4.0 g upon the renal excretion of uric acid was determined using an identical protocol on the seventh, ninth and thirteenth hosGta1 days, respectively.
The effect of extracellular fluid volume expansion upon the excretion of uric acid was examined on the e1e;enth hos<ital day as described by Manuel and Steele (19) . After an overnight fast, the patients drank 20 ml/kg of tap water. Oral hydration throughout the study consisted of tap water equal to urine volume. Three 30-min control collections of urine were obtained with venous blood samples drawn midway during the first and at the end of the third collection. Immediately after the final control period, an intravenous infusion of 3% sodium chloride at a rate of 20 ml/ 1.73 m2/min was continued for 80 min. Four collections of urine of 20 min duration and midpoint specimens of venous blood were obtained during the saline infusion.
RESULTS

URIC ACID SYNTHESIS AND EXCRETION
Urinary excretion of oxypurines in family S is listed in Table 2 . The total amounts of oxypurine excreted ranged from 0.18 to 0.92 mg/mg creatinine which is similar to normal individuals (37, 38) . The largest excretion of o x y p u~e , 0.92 mg/mg creatinine, occurred in the youngest patient which is consistent with normal developmental patterns (16) . In the presence of allopurinol, the molar ratios of hypoxanthine to xanthine varied from 0.21 to 0.73, which is the expected response (38). In none of these patients was the urinary excretion of uric acid increased. In SIV,, eight 24-hr urine collections while taking no allopurinol and eating a purinefree diet contained 294 to 444 mg/24 hr (mean 377 mg). The excretion of organic acids in the urine was normal; therefore, no compounds that might compete for renal tubular secretion of uric acid were identified.
Assay of the activity of HGPRT in the erythrocytes of all hyperuricemic members of family S gave values ranging from 1993 to 2873 pM/IMP/min/ml packed cells at saturating concentration of substrates and from 1181 to 1308 at concentrations of the K,. The mean values were 2527 and 1257, respectively. Those for the father were 2197 and 1075, respectively. These are all normal values. The mean for APRT in the six involved individuals was 674 and that of the father was 556 yM/AMP/min/ml packed cells. Electrophoretic analysis of HGPRT and APRT in SIVl and his mother revealed a normal pattern of migration. The activity of phosphoribosyl pyrophosphate (PRPP) synthetase in the four boys and the mother ranged from 63.6 to 79.2 pM/hr/mg protein. The mean was 74.5; and the value for the father was 65.2. These data, obtained after 9 to 10 days without allopurinol, were normal, as were those for the concentration of PRPP in erythrocytes. In SIVZ the concentration was 1.47 pM/ml packed cells, and in SI14 and a control individual the values were 3.8 and 3.55. The assay was repeated after 20 days without allopurinol and the values were 3.65 mpM/ml packed cells in SIVz and 3.0 mpM/ml packed cells in a control individual. An assay for GMP synthetase in SIV2 revealed an activity of 16,150 DPM compared to 13,179 DPM in a control individual. Similarly, assays for adenosine deaminase, adenylate deaminase, 5'nucleotidase and nucleoside phosphorylasewere normal in SIV2.
After the injection of labeled glycine in patient SI14, there was a rapid appearance of I3C and I4C in respiratory COZ. The isotope content approached maximum at 15 min, continued to rise about 5% in the next 15 min and then fell progressively over 240 min of study to values about 20% of those at the peak. Thus there was a normal pattern of rapid oxidation of glycine. The data for I4C and for I3C agreed precisely at each of the five points studied. The specific activity of urinary uric acid increased in the first 12 hr to a low plateau of approximately 100 DPM/mg which was maintained throughout the 7 days of study. This is the pattern observed in individuals with normal purine metabolism-and lacked the early spike seen in individuals with overproduction of purine de novo (19) . The curve for the cumulative percent of the isotope of glycine found in urinary uric acid rose gradually from 0.01 at 12 hr, to 0.08 at 24 hr, to 0.12 by day 2, to 0.14 by day 4, to 0.20 by the end of day 7. This was a normal rate of incorporation reflecting a normal rate of purine synthesis.
Urinary and serum uric acid values in family B are listed in Table 3 . Urinary excretion of uric acid was not elevated in any of the hyperuricemic individuals. Normal values for clearance of uric acid (C~~)/clearance of creatinine (Cc,) x 100 are 8 to 12% and for U U A / U~, are ~1 . 0 (9, 14) . In BI16, activity of erythrocyte HGPRT was 1726 and 995 pM/IMP/min and APRT 565 pM/ IMP/min/ml packed cells (all normal). Thus there is no evidence of overproduction of uric acid in BI16 and the clearance of uric acid was diminished in each affected family member.
PHYSIOLOGY OF RENAL EXCRETION OF URIC ACID
The concentrations of uric acid in the serum and urinary excretion of uric acid in SIVz and BI16 after three days of a purinefree diet are listed in Table 4 along with data on renal function. There was diminished fractional excretion of uric acid (FEVA) in each (4.8 and 3.8). All other indices of renal function measured were normal. Urinalyses were also normal in each patient. The serum concentrations of bicarbonate were 25 and 26 mEq/liter, while the first morning urinary pH was 5.5 and 5.3 and SIV2 and BI16, respectively. After a 12-hr fast, maximal urinary osmolality was 947 mOsm/kg Hz0 in patient BIIs. Renal concentrating ability was not examined in patient SIV2. In neither patient was the total excretion of uric acid increased (normal <700 mg/24 hr) (10, 21, 23, 30) . Minimal renal tubular secretion of uric acid (TSu.4) was estimated using the pyrazinamide (PZA) suppression study. The Table 5 . PZA study in patient results of the PZA suppression studies are shown in Tables 5 and  6 . The serum concentration of uric acid (Sun) increased in both patients while the CUA and the FEUA decreased from 7.9 to 0.7%. During the study, Cc,, urinary flow rate (V) and remained nearly constant or decreased minimally in BI16. In SIV2, CC,, V, C N~, and clearance of phosphate (Cp) increased. The TSUA estimated by the PZA suppression study was 0.39 mg/min/100 ml Cr in SIV2 and 0.41 mg/min/100 ml Cc, in BIIs which was within the range of normal values reported by Steele and Rieselbach (32) . Tubular reabsorption of uric acid (TRuA) in both patients was nearly complete (99.2 and 99.3%).
To characterize further the renal tubular reabsorption of uric acid, probenecid, an inhibitor of uric acid reabsorption, was administered. As shown in Table 7 , each patient exhibited a brisk uricosuric response to 2.0 g probenecid. Urate excretion increased by 3.97 and 3.19 mg/min which was nearly twice the uricosuric response of 1.67 + 0.384 mg/min reported in normal young adults by Diamond et al. (8) . The serum concentrations of uric acid decreased from 8.4 to 6.9 mg/dl and from 9.8 to 8.8 mg/dl. Cc, and Cp did not change during the study. The urinary flow rate increased from 14 to 20.3 ml/min in patient SIV2 but did not change after probenecid administration in BI16. FEN, increased from 0.5 to 1.0% and from 0.8 to 1.8% in SIVz and BI16. PZA has been shown to inhibit the uricosuric response to probenecid in healthy adults (8) . This finding supports the concept of tubular reabsorption of uric acid distal to secretory sites. Comparing the uricosuric response to probenecid alone with that of the combination of probenecid and PZA allows a minimal estimation of post-secretory reabsorption of uric acid. PZA markedly attenuated the uricosuric response to probenecid. Uric acid excretion increased from 0.47 to 0.55 mg/min and from 0.50 to 0.67 mg/min, respectively (Table 7) . Probenecid sensitive postsecretory uric acid reabsorption was therefore 3.89 and 3.02 mg/min which was substantially greater than the mean response of 1.579 mg/min previously reported in normal adults (8) .
Expansion of the extracellular fluid space produces a uricosuric response in some adults, presumably by inhibiting tubular reabsorption of uric acid (19) . In patient SIV2, infusion of 3% NaCl (8) .
SZV2, symbols are niven in text
resulted in a 4.9% increase of the chloride space and Cc, decreased from 135 to 130 ml/min/1.73 m2. CUA decreased from 4.76 to 3.8 ml/min/1.73 m2 and uric acid excretion decreased from 0.42 to 0.27 mg/min. Serum concentration of Na rose from 139 to 15 1 mEq/liter while urinary flow rate decreased from 13 to 0.9 ml/ min. FEN, rose from 0.2 to 1.1%. Hypertonic saline infusion increased the chloride space by 12% in patient BII6. Ccr increased from 139.5 to 153 ml/min/1.73 m2. CUA increased from 3.95 to 11.3 ml/min/1.73 m2. FEUA increased from 2.8 to 7.4% while FEN, increased from 0.9 to 4.8%. Serum Na increased from 143 to 147 mEq/liter. Urinary flow rate was 10 ml/miil during the control period and also during the peak uricosuric collection. Manuel and Steele (19) have previously reported considerable variability in the uricosuric response to hypertonic NaC1; five of ten subjects increased FEUA by 5 to 6.6%. Neither of our patients demonstrated a marked uricosuric response although patient BI16 increased FEUA by 4.6%. Ascorbic acid has also been shown to increase urinary excretion of uric acid (34) . The uricosuric response to ascorbic acid is inhibited by PZA suggesting that ascorbic acid either stimulates TSUA or inhibits postsecretory reabsorption of uric acid. After ingesting 4.0 g ascorbic acid, patient SIVz increased CUA from 7.7 to 15 ml/min/1.73 m2, F E~A from 4.3 to 1 1.5% and uric acid excretion from 0.61 to 1.02 mg/min. The serum concentration of uric acid decreased from 8.18 to 6.8 mg/dl. Urine flow increased from 7.2 to 9.6 ml/min; Cp and CN, increased minimally from 10.7 to 12.1 and from 0.7 to 0.9 ml/min at the time of maximal uricosuric response. After patient BII6 ingested ascorbic acid, FEUA increased only minimally from 4.6 to 5.4% and the serum concentration of uric acid increased from 7.1 to 7.3 mg/dl. All six hyperuricemic individuals in family B were given ascorbic acid for 6 wk. Two individuals were given 8.0 g daily, two received 4.0 g daily, and two individuals received 2.0 g daily. None of the patients demonstrated a uricosuric response either by increasing the UUA/UC, ratio or by decreasing the serum concentration of uric acid. In fact, the serum concentration of uric acid increased slightly in three and remained constant in the remainder. The mean pretreatment value was 8.1 mg/dl (range 7.1 to 9.6) and the mean posttreatment value was 8.4 mg/dl (range 7.9 to 10.1).
PROTEIN BINDING
Binding of uric acid to plasma proteins was determined by equilibration dialysis. The serum to bath ratios of 2-14C uric acid were 0.99 and 1.02 after 30 hr of dialysis in patients SIVz and B I 4 respectively. These data suggest that increased binding of uric acid to plasma proteins was not present and that neither the impaired renal excretion of urate during control conditions nor the uricosuric response to probenecid are influenced by protein binding of uric acid.
DISCUSSION
The pathogenesis of the elevated concentrations of serum in the uric acid of patients with familial hyperuricemia and gout has not been the subject of systematic study. In general, hyperuricemia results from excessive production of uric acid or its impaired renal elimination. The role of the kidney in the pathogenesis of hyperuricemia has been emphasized by Seegmiller et al. (26) who demonstrated impaired renal clearance of uric acid in five hyperuricemic individuals in whom excessive production of uric acid had been excluded. These observations were extended by Rieselbach et al. (24) who used the PZA suppression test to identify diminished renal tubular secretion of uric acid in six gouty patients with normal endogenous production of uric acid. Previous studies of pathogenesis and the role of the kidney in primary gout have not segregated patients with familial hyperuricemia (9, 33) .
In family S and family B the apparent mechanism for the accumulation of uric acid in body fluids was renal. Studies on family S clearly excluded overproduction of uric acid. The total amounts of oxypurine excreted in the urine were not excessive, and the rate o f synthesis of uric acid in vivo from isotopically labeled glycine was normal. Assay of the activity of a number of enzymes of purine metabolism were also normal. The amounts of uric acid excreted in the urine in family B were similar to those of family S, and the enzyme actions assayed were also normal. The impaired renal clearance of uric acid in our patients was not a consequence of a decreased rate of glomerular filtration or an increased binding of uric acid to plasma proteins. Thus, we inferred that there was either decreased renal tubular secretion or increased reabsorption.
The minimal rate of tubular secretion of uric acid in man has traditionally been assessed by the administration of pyrazinamide; its metabolite.vvrazinoic acid at low ~l a s m a concentration inhibits the secretion bi. uric acid (32) . ~ieselbach et al. (24) concluded that the renal secretion of uric acid was reduced in some hyperuricemic patients in whom rates of production of uric acid were normal, particularly in view of elevated concentrations of uric acid in the serum. Gutman et al.
( 1 1) were unable to identify a defect in tubular secretion of uric acid in a series of patients with gout in which subjects were not segregated on the basis of endogenous production of uric acid. Questions have been raised concerning the specificity and reliability of determining the rate of secretion of uric acid (13, 32) . Since tubular secretion may occur concurrently with reabsorption of urate, the PZA test may underestimate the magnitude of secretion of uric acid. Data from pyrazinamide suppression studies cannot totally exclude the possibility that a subnormal rate of tubular secretion exists at elevated concentrations of uric acid in serum. Nevertheless, the response of normal adults to PZA is reproducible and offers a comparative standard for patients with hyperuricemia. Neither SIV2 nor BI16 had a subnormal response to pyrazinamide, sugges~ing that decreased secretion of uric acid was not the etiology of the low urate clearance. Probenecid partially inhibits the renal tubular reabsorption of uric acid. Both of our patients had a dramatic uricosuric response after probenecid with uric acid excretion increasing more than 3 mg/min. Normal adults studied by Diamond et al. (8) increased their excretion of uric acid by a mean of 1.57 mg/min after probenecid. Similarly, the excretion of uric acid increased by a mean 1.76 mg in 10 gouty subjects given probenecid (28) . These data, along with the normal pyrazinamide suppressible fraction of STAPLETO uric acid, suggest that enhanced tubular reabsorption of uric acid was responsible for the hyperuricemia in these patients.
PZA has been shown to diminish markedly the uricosuric response to probenecid in man (32) . This inhibitory effect of PZA upon the uricosuric response to probenecid has supported the concept of postsecretory reabsorption of uric acid. Conclusions from the comparison of the uricosuric response to probenecid alone with a combination of PZA and probenecid require the exclusion of drug-drug interactions. Although we cannot exclude inhibition of secretion of probenecid into the proximal tubule by pyrazinamide, Meisel and Diamond (20) have demonstrated that PZA has no effect on excretion of probenecid in adult human subjects. These authors concluded that PZA inhibits the uricosuric effect of probenecid either by preventing the delivery of secreted urate to distal reabsorptive sites or by interfering with the action of probenecid at the luminal membrane (20) . If we accept the interpretation that PZA acts by inhibiting urate secretion, then the nearly complete inhibition of the uricosuric response to probenecid by PZA in our patients suggests that the primary site of the increased tubular reabsorption of uric acid was distal to secretory sites.
Tubular reabsorption of uric acid has been characterized experimentally in animals. It appears that reabsorption of uric acid is an active process (25) ; the concentration of uric acid in proximal tubular fluid decreases below plasma levels to a degree which could not be maintained by transepithelial potential difference. This conclusion is supported by data from studies of uric acid transport in brush-border vesicles (5, 7). Other factors that affect the proximal tubule reabsorption of uric acid include the rate of urine flow, the concentration of glucose in the urine, and the pH gradient (5, 6, 15. 27) . The relationship of these characteristics to the enhanced reabsorption of uric acid in our patients is not clear. No other tubular abnormalities were evident in our patients. Tubular reabsorption of phosphate and sodium were normal, and there were no elevations of plasma concentrations of calcium or bicarbonate. Infusion of hypertonic sodium chloride produced a modest uricosuric response in patient BII6. In SIV2, creatinine clearance, urine flow rate, and excretion of uric acid fell while the fractional excretion of sodium increased 5-fold. In this patient, the chloride space increased by 4.9% and the serum concentration of sodium increased from 139 to 15 1 mEq/liter.
It is of interest that ascorbic acid produced a uricosuric response in patient SIVP but did not increase the excretion of uric acid in any of the hyperuricemic members of family B. These findings raise the possibility that the site or mechanism of increased reabsorption of urate in these two families may differ.
The literature on the genetic transmission of hyperuricemia has been controversial. Talbot (39) found that 34 of 136 asymptomatic relatives of patients with gout had serum concentrations of uric acid greater than 6.0 mg/dl, and 80% of the hyperuricemic relatives were male. Smyth et al. (29) studied 19 families with hyperuricemia and concluded that the distribution of hyperuricemic offspring was compatible with an autosomal dominant gene. Similarly, Stecher et al. (3 1 ) evaluated 201 members of 44 families with gout and concluded that hyperuricemia was inherited as an autosomal dominant gene in some families and autosomal recessive in other families, or as an autosomal dominant gene with low penetrance in females. Hauge and Hawald (12) concluded that familial hyperuricemia could best be explained by multifactoral inheritance. A similar conclusion was reached by Neel et al. (22) who evaluated families initially evaluated by Smyth et al. (29) and found less convincing evidence for autosomal dominant inheritance and therefore suggested multifactoral inheritance.
Analysis of the pedigrees of family S and family B yields a conclusion of a dominant pattern of inheritance. It is also clear in family S that the expression of the disease is milder in females than in males. In each of two generations, the contrast between the rather mild expression in the sister with the rapidly lethal disease in their brothers is striking. It is impossible to distinguish whether this family represents sex modification of an autosomal dominant gene or heterozygosity for an X-linked dominant gene. There was no male to male transmission in family S. In contrast, in family B, inheritance was clearly autosomal dominant. Only males were found to be hyperuricemic and there was male to male transmission.
